These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial. Kandasamy R; Gurung M; Thorson S; Yu LM; Galal U; Voysey M; Kelly S; Wahl B; Berbers G; Finnegan K; Ansari I; Paudel K; Murdoch DR; O'Brien KL; Kelly DF; Goldblatt D; Shrestha S; Pollard AJ Lancet Infect Dis; 2019 Feb; 19(2):156-164. PubMed ID: 30635252 [TBL] [Abstract][Full Text] [Related]
24. Pneumococcal carriage in children in Ulaanbaatar, Mongolia before and one year after the introduction of the 13-valent pneumococcal conjugate vaccine. von Mollendorf C; Dunne EM; La Vincente S; Ulziibayar M; Suuri B; Luvsantseren D; Narangerel D; Ortika BD; Pell CL; Nation ML; Alamrousi A; Hinds J; Demberelsuren S; Nguyen C; Mungun T; Mulholland EK; Satzke C Vaccine; 2019 Jul; 37(30):4068-4075. PubMed ID: 31174939 [TBL] [Abstract][Full Text] [Related]
25. Invasiveness potential of pneumococcal serotypes in children after introduction of PCV13 in Blantyre, Malawi. Kirolos A; Swarthout TD; Mataya AA; Bonomali F; Brown C; Msefula J; Bar-Zeev N; Iroh Tam PY; Alaerts M; Bilima S; Heyderman RS; French N BMC Infect Dis; 2023 Jan; 23(1):56. PubMed ID: 36703117 [TBL] [Abstract][Full Text] [Related]
27. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461 [TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial. Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992 [TBL] [Abstract][Full Text] [Related]
29. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control studies. Bar-Zeev N; Swarthout TD; Everett DB; Alaerts M; Msefula J; Brown C; Bilima S; Mallewa J; King C; von Gottberg A; Verani JR; Whitney CG; Mwansambo C; Gordon SB; Cunliffe NA; French N; Heyderman RS; Lancet Glob Health; 2021 Jul; 9(7):e989-e998. PubMed ID: 34143997 [TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of alternative ten-valent pneumococcal conjugate vaccine schedules in infants in Ho Chi Minh City, Vietnam: results from a single-blind, parallel-group, open-label, randomised, controlled trial. Licciardi PV; Temple B; Dai VTT; Toan NT; Uyen D; Nguyen CD; Phan TV; Bright K; Marimla RA; Balloch A; Huu TN; Mulholland K Lancet Infect Dis; 2021 Oct; 21(10):1415-1428. PubMed ID: 34171233 [TBL] [Abstract][Full Text] [Related]
31. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage Rates of Streptococcus pneumoniae in a Rural Community in the Dominican Republic. Dunn MG; Lessa FC; Sánchez J; Cordero R; Feris-Iglesias J; Cedano D; Carvalho MDG; Fernández J; Feemster KA J Infect Dis; 2021 Sep; 224(12 Suppl 2):S237-S247. PubMed ID: 34469551 [TBL] [Abstract][Full Text] [Related]
32. Effectiveness of Pneumococcal Conjugate Vaccines Against Community-acquired Alveolar Pneumonia Attributable to Vaccine-serotype Streptococcus pneumoniae Among Children. Lewnard JA; Givon-Lavi N; Dagan R Clin Infect Dis; 2021 Oct; 73(7):e1423-e1433. PubMed ID: 33346348 [TBL] [Abstract][Full Text] [Related]
33. Changes in pneumococcal carriage prevalence and factors associated with carriage in Norwegian children, four years after introduction of PCV13. Løvlie A; Vestrheim DF; Aaberge IS; Steens A BMC Infect Dis; 2020 Jan; 20(1):29. PubMed ID: 31924177 [TBL] [Abstract][Full Text] [Related]
34. PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children. Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA Vaccine; 2017 Feb; 35(6):945-950. PubMed ID: 28087146 [TBL] [Abstract][Full Text] [Related]
35. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study. Pichichero M; Kaur R; Scott DA; Gruber WC; Trammel J; Almudevar A; Center KJ Lancet Child Adolesc Health; 2018 Aug; 2(8):561-568. PubMed ID: 30119715 [TBL] [Abstract][Full Text] [Related]
36. Changing Incidence of Invasive Pneumococcal Disease in Infants Less Than 90 Days of Age Before and After Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Blantyre, Malawi: A 14-Year Hospital Based Surveillance Study. Koenraads M; Swarthout TD; Bar-Zeev N; Brown C; Msefula J; Denis B; Dube Q; Gordon SB; Heyderman RS; Gladstone MJ; French N Pediatr Infect Dis J; 2022 Sep; 41(9):764-768. PubMed ID: 35703302 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae. Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA J Infect Dis; 2015 Apr; 211(7):1144-53. PubMed ID: 25355940 [TBL] [Abstract][Full Text] [Related]
38. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458 [TBL] [Abstract][Full Text] [Related]
39. Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium. Wouters I; Desmet S; Van Heirstraeten L; Blaizot S; Verhaegen J; Van Damme P; Malhotra-Kumar S; Theeten H; Vaccine; 2019 Feb; 37(8):1080-1086. PubMed ID: 30665775 [TBL] [Abstract][Full Text] [Related]
40. Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-serotype community acquired pneumococcal diseases among children in China: A test-negative case-control study. Xiaofei L; Yudan LI; Qinghui C; Jiaming S; Benfeng Z; Youyi Z; Biying W; Lijun Y; Jun Z; Jianmei T; Lin L; Xuejun S; Genming Z; Tao Z Vaccine; 2024 Feb; 42(6):1275-1282. PubMed ID: 38296700 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]